Commentary

Video

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

Author(s):

Mariya Rozenblit, MD

Fact checked by:

Ashling Wahner ,Chris Ryan

In Partnership With:

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine, discusses findings from a study evaluating the prevalence of actionable genomic alterations and the predictive value of tumor mutational burden (TMB) for the efficacy of immune checkpoint inhibitors in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Related Videos
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Tracy George, MD
Elias Jabbour, MD
Neil Iyengar, MD, and Chandler Park, MD, FACP
Bently P. Doonan, MD
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Related Content
Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 12th 2024

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
December 12th 2024

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

ASH Annual Meeting | Image credit: © Nittaya – stock.adobe.com
December 12th 2024

Optimizing Treatment Sequences Remains Key in CLL/SLL

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 12th 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia